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Abstract 
The  complex  picture  of  inflammation  and
coagulation alterations comes to life in acute
stroke phases. Increasing evidence points to a
strong  interaction  and  extensive  crosstalk
between  the  inflammation  and  coagulation
systems: the interest towards this relationship
has  increased  since  recent  experimental
research showed that the early administration
of antithrombin III (ATIII) decreases the vol-
ume of ischemia in mice and might be neuro-
protective, playing an antiinflammatory role.
We aimed to establish the extent of the rela-
tionship  among  markers  of  inflammation
(S100B and IL-18) and procoagulant and fibri-
nolytic markers (ATIII, thrombin-antithrombin
III complex (TAT), Fibrin Degradation Products
(FDP),  D-dimer)  in  13  comatose  patients
affected by focal cerebral ischemia.
Plasma levels of TAT, D-dimer and FDP, IL18
and S100B were increased. IL-18 and S100B
high serum levels in ischemic patients suggest
an  early  activation  of  the  inflammatory  cas-
cade in acute ischemic injury.
The  basic  principles  of  the  interaction
between  inflammatory  and  coagulation  sys-
tems  are  revised,  from  the  perspective  that
simultaneous modulation of both coagulation
and inflammation, rather than specific thera-
pies aimed at one of these systems could be
more successful in stroke therapy. 
Introduction
Thrombin antithrombin complex in
brain ischemia
Procoagulant or impaired fibrinolytic states
as well as inflammatory reactions mediated by
cytokines are very likely involved in the patho-
genesis of acute ischemic stroke
1 (Table 1).
Toll-like receptors (TLRs) are critical com-
ponents  of  the  innate  immune  system  that
have been shown recently to mediate ischemic
injury.
7,8 Host-endogenous molecules associat-
ed with damaged cellls and tissues have been
demostrated to activate TRLs. TLRs are located
on antigen presenting cells such as B cells,
dendritic  cells,  monocytes/macrophages  and
microglia.
9-11 The TLRs signal through common
intracellular pathways leading to transcription
factor  activation  and  the  generation  of
cytokines and chemokines.
12,13 TRL2 and TRL4
have  been  shown  to  play  a  role  in  cerebral
ischemic  damage.  The  TLR  endogenous  lig-
ands HSP 60, HSP70 and HMGB1 have been
found in the brain following injury;
14-16 hence,
these molecules may activate TLR2 and TLR4
within the brain itself, leading to the genera-
tion of inflammatory mediators such as TNFʱ,
IL1, IL6, and I NOS, all known to be associated
with stroke damage.
During focal cerebral ischemia, alterations
in the hemostatic system, platelet activaction
and  changes  in  the  plasminogen  activactor-
inhibitor  axis  take  place,  particularly  in  the
acute  phase  when  there  is  an  elevation  of
thrombin activity and a depressed fibrinolytic
activity.
17,18
The conversion of prothrombin into active
thrombin is a key event within the coagulation
cascade. Thrombin is a serine protease and an
essential component in the coagulation cas-
cade. Direct infusion of large doses of throm-
bin into the brains of animals causes inflam-
matory-cell infiltration, mesenchymal-cell pro-
liferation, scar formation, brain oedema for-
mation, and seizures.
19-26 Thus, early oedema
formation involves activation of the coagula-
tion cascade and thrombin production.
22
Thrombin acts on various physiological sub-
strates (fibrinogen, protein C, platelets, etc.)
and is inhibited by antithrombin III, resulting
in  an  inactive  proteinase/inhibitor  complex
(TAT complex) (Figure 1).
ATIII is an important endogenous inhibitor
of serine proteases that are generated within
the coagulation cascade. Clinically, it has been
widely  used  in  patients  admitted  to  ICU  as
treatment  for  ATIII  deficiency,  treatment  of
sepsis or disseminated intravascular coagula-
tion. Recently, it has been demonstrated that
ATIII may have other functions in addition to
its role in inhibiting clotting. O’ Reilly et al.
27
have  shown  its  remarkable  antiangiogenetic
and  antitumor  activities.  In  addition,  some
investigators  have  reported  that  ATIII  sup-
presses leukocyte infiltration and subsequent
tissue damage in endotoxin-induced vascular
injury
28 or  ischemia-reperfusion  injury.
29,30 In
the  field  of  septic  shock,  the  suppressive
effects  of  ATIII  on  inflammation  have  been
highlighted.
31,32 In patients with severe sepsis,
treatment with ATIII improved lung function
and prevented septic liver and kidney failure.
33
ATIII has attracted a great deal of attention as
a possible treatment for these various condi-
tions;  because  no  adverse  side  effects  have
been reported in human trials.
34 However, little
information is available about the effects of
ATIII  on  cerebral  ischemia  and  the  mecha-
nisms of its antiinflammatory action.
When generated endogenously or adminis-
tered  intravenously,  ATIII  is  tethered  to  the
wall of the microvasculature with the help of
heparin and it is then bound to the active site
on thrombin to suppress its functions. In addi-
tion to its hemostatic role, thrombin has the
ability  to  induce  interactions  between
endothelial cells and blood-flowing cells, such
as  leukocytes
35-37 or  tumor  cells.
38,39 Because
these interactions are thought to be the initial
step in leukocyte infiltration, tumor invasion,
or  metastasis,
40,41 the  antiinflammatory  and
antitumor  properties  of  ATIII  may  be  based
partially  on  its  suppressive  effects  on  these
interactions.
In addiction, recent experimental research
showed  that  the  administration  of  ATIII
decreases the volume of ischemia in mice and
might  be  neuroprotective.
42 Detecting  and
monitoring activation of the coagulation sys-
tem in ischemic stroke with conventional labo-
ratory tests is difficult because the tests lack
adequate sensitivity and specificity. The recent
development  of  immunochemical  assays  has
allowed the detection of intermediate break-
down products of fibrin formation and fibrinol-
ysis.
43,44 Among these, thrombin-antithrombin
III (TAT) complex reflects thrombin activation
and  fibrin  formation,  while  D-dimer  marks
plasmin activity and fibrinolysis.
45-48
IL18 
IL-18, previously termed IFN-alpha-inducing
factor, is a member of the IL-1 family, a large
group of pro-inﬂammatory cytokines. It is syn-
thesized as an inactive 24-kDa precursor pro-
tein (pro-IL-18) that is subsequently processed
by caspase-1 into its mature and biologically
active form, which has a molecular weight of
18kDa.  The  secreted  pro-IL-18  can  also  be
processed into its active form by various extra-
cellular  enzymes  constitutively  expressed  by
leukocytes,  such  as  proteinase-3.  The  active
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binding to its heterocomplex IL-18ʱ/b receptor
expressed on diverse cell-types These include
cells resident in the CNS, such as hypothalam-
ic neurons and murine glia.
Beyond the CNS, the biological effects of IL-
18 binding to IL-18R include induction of Th1
and Th2 helper T-cell responses and of cytotox-
ic activity by natural killer cells, in addition to
propagation  of  intrinsic  and  extrinsic  path-
ways of apoptosis. IL-18 is a ‘key’ cytokine in
the CNS, controlling two distinct immunologi-
cal  regulatory  pathways  of  cytotoxic  and
inﬂammatory responses under neuropatholog-
ical conditions (Table 2). 
S100B
S100B,  a  low-molecular-weight  calcium-
binding protein, is most abundant in glial cells
of the central nervous system, predominately
in  astrocytes.  Initially  these  proteins  were
thought to be brain-specific, but later studies
have shown that S100 proteins are found in
other tissues, albeit in much lower concentra-
tions than those found in the CNS
53 (Table 3).
Astrocytes dominate the cellular regulation
of homeostasis and are immediately activated
after primary brain injury. S100B is involved
specifically in this process by regulation of cal-
cium fluxes and stimulation of astrocyte prolif-
eration.
Intracellulary,  S100B  is  involved  in  signal
transduction  via  the  inhibition  of  protein
phoshorylation, regulation of enzyme activity
and  by  affecting  the  calcium  homeostasis.
S100B serum level is increased in a variety of
CNS  disorders:  in  cerebral  ischemia  it  has
been associated to infarct size, neurovascular
status on admission and outcome.
54 Although
in many instances its release may be an effect
of the condition rather than the cause, it is
nonetheless  strongly  implicated,  and  can  be
considered to be a strong candidate as a surro-
gate marker of CNS injury.
S100B,  is  involved  in  cytokine  cascade
53
(Figure 1). Secreted S100B can therefore be
compared to the circulating pro-inflammatory
cytokines,  since,  like  interleukin  1  (IL1),  it
promotes neuronal survival at low concentra-
tions but is neurotoxic at high levels. 
Materials and Methods
We  aimed  to  establish  the  relationship
between  markers  of  the  inflammatory
response (IL-18 and S100B) and procoagulant
and fibrinolytic markers (AT III, TAT, D-dimer,
FDP), in patients with cerebral ischemia, and
to investigate the association of brain inflam-
matory markers (S100B and IL-18) and severi-
ty of coma. Only a few markers were chosen
because of particular interest, but this choice
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Figure 1. Schematic rappresentation of activation of coagulation and inflammation during
cerebral ischemia. Exposure of tissue factor-bearing inflammatory cells to blood results in
thrombin generation and subsequent fibrinogen to fibrin conversion. Simultaneously, activa-
tion of platelets occurs, both by thrombin and by exposure of collagen (and other subendothe-
lial platelet-activating factors) to blood. Binding of tissue factor, thrombin, and other activat-
ed coagulation proteases to specific PARs on inflammatory cells may affect inflammation by
inducing release of proinflammatory cytokines (such as IL-18), which will subsequently fur-
ther  modulate  coagulation  and  fibrinolysis.  Fibrinogen  and  fibrin  can  directly  stimulate
expression of proinflammatory cytokines on mononuclaer cells and induce production of
chemokines by endothelial cells and fibroblast. The effects of fibrin (and fibrinogen) on
mononuclear cells are at least in part mediated by toll-like receptors (TLR2-4), which are also
the receptors of endotoxin. S100 b at supraphysiological concentration can stimulate astro-
cytes and microglia to produce proinflammatory cytokine. Coagulation pathways are indicat-
ed by straight arrows, inflammatory mechanisms by dashed arrows.
Table 1. Thrombin-antithrombin III complex in literature.
Authors Journal Type  Results Conclusions
of study
Kataoka S
2 Neurol Sci  Coagulation markers CEI:>TAT, FpA,  Alterations in thrombotic
(2000) in atherothrombotic  D-dimer, <ATIII and fibrinolytic markers
infarct (ATI),  ATI: >TAT, FpA, should contribute to
cardioembolic  D-dimer, ATIII normal the clinical diagnosis
infarct (CEI) and  LI: No significant >TAT,  of brain infarct subtypes
lacunar infarct (LI) d-dimer, FpA
Ince B
3 Thromb Coagulation and >TAT and FpA Hemostatic abnormalities
Res  fibrinolysis in >>D-dimer have a primary role




4 Acta  Coagulation and >D-dimer Minor changes
Neurol  fibrinolytic TAT stable of the fibrinolytic and
Scand markers in  coagulation system
(2004) acute and  activity in the patients
convalescent  with mild ischemic
phase of ischemic  stroke
stroke
Ilzecka S
5 Neurol  TAT in ischemic >>TAT Intense
Neurochir stroke patients thrombinogenesis
Pol (2001)
Haapaniemi E
6 Acta Neurol ATIII in mild and >>ATIII Natural anticoagulants
Scand moderate ischemic  No correlation levels did not deliver
(2002) stroke with etiology of stroke,  useful information
any stroke risk factor 
or neurological scores
FpA, fibrinopeptide A.cannot imply a completely exhaustive presen-
tation of the topic.
An audit of stroke outcome and procedures
was designed in ICU patients; the study proto-
col was reviewed and approved by the Hospital
Ethics  Committee  (University  hospital  of
Naples, “Federico II”).
Thirteen comatose patients following acute
stroke admitted in our ICU in one year time
were studied. 
The inclusion criteria were the following:
- no prior history of ischemic stroke (defined
as  a  rapid  developing  focal  neurological
deficit with no apparent signs other than a
vascular origin); 
- ICU  admission  within  24h  after  stroke
onset;  
- lesion  confirmed  by  neuroradiological
examination (brain CT).
To assess the natural course of coagulatory
changes following brain infarct, and to avoid
the  enrollement  of  patients  with  concurrent
diseases  or  conditions  interfering  with  the
expression of inflammatory mediators, the fol-
lowing exclusion criteria were applied: 
- presence  of  infections,  inflammatory,
autoimmune, hamatologic or malignant dis-
eases;
- severe renal or liver failure;
- thrombolisis, 
- abnormalities induced by deep vein throm-
bosis, disseminated intravascular coagula-
tion and collagen vascular disease.
- thrombolitic treatment.
In all patients, we measured the plasma lev-
els  of:  thrombin-antithrombin  III  complex
(TAT), D-dimer, Fibrin Degradation Products
(FDP), percent activity of ATIII and IL-18 at the
1st and 5th (two time points) day after the
stroke onset, S100B serum levels within the
first 24 h (one time point). All patients were
evaluated using Simplified Acute Physiologic
Score (SAPS) III on admission day, Sequential
Organ  Failure  Assessment  (SOFA)  and
Glasgow Coma Scale (GCS) every day. 
Patients were divided in two groups accord-
ing to coma severity:
Group 1) GCS≤8
Group 2) GCS>8
Data were expressed as mean ± standard
deviation; the significance of the differences
among the groups was assessed using ANOVA
test and a randomness level of P<0.05 was con-
sidered statistically significant. 
Measurement of coagulation mark-
ers
Plasma concentrations of TAT were deter-
mined  by  enzyme-linked  immunoassay
(EIA)/Enzygnost TAT micro, Behring, Marburg,
Germany). The concentrations of D-dimer and
FDP  were  determined  by  latex  photometria
immunoassay  (LPIA)  (DIA-IATRON,  Tokyo,
Japan). The measurements of ATIII biological
activity  were  performed  by  the  amidolytic
method. Venous blood was sampled from the
antecubital vein and then measured within 3h
after blood sampling. TAT, ATIII and D-dimer
were  collected  in  tubes  containing  3.8%
trisodium citrate. These plasma samples were
separated by centrifugation at 2300xg for 15
min at room temperature and then stored at -
80° until needed for assay.
Measurement of IL-18
The  samples  obtained  by  the  antecubital
venipuncture were allowed to clot at room tem-
perature  for  30  min,  and  after  being  cen-
trifuged for 10 min, the serum was immediate-
ly frozen. IL-18 serum levels were quantified by
ELISA (MBL, Naka-ku Nagoya, Japan) accord-
ing to the manufacturer’s instructions (normal
value 155.7±51.4 pg/mL
50 Value of our control
group  of  10  volunteers,  age  28±1.3,  20%
women, is 168.9±40 pg/mL).
S100B analysis
A peripheral blood sample of S100B was ana-
lyzed in duplicate using a monoclonal two-site
immunoradiometric  assay  (LIAISON

Sangect
 100). The lower limit detection was
0.02 ʼg/L (normal value <0.15 ʼg/L).
17
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Table 2. IL18 in literature.
Authors Journal Type  Results Conclusions
of study
Zaremba J
50 Neurol Sci IL-18 in stroke  Elevated serum IL-18 is involved in
(2003) patients IL18 levels in stroke stroke-induced
patients inflammation
Mallat Z
51 Circulation IL18 mRNA Significantly Major role for IL-18
(2001) in stable and  higher levels in atherosclerotic 
unstable human  of IL-18 mRNA plaque destabilization
carotid  were found in leading to acute
atherosclerotic  symptomatic (unstable)  ischemic syndromes
plaques plaques than asymptomatic 
(stable) plaques
Yuen CM
52 Circ  J IL-18 in ischemic Elevated IL18 levels  Evaluation
(2007) stroke patients of circulating






Table 3. S100 b in literature.
Authors Journal Type  Results Conclusions
of study
Jackson RG
54 Clin Chem S100 bin  Levels of S-100 S100 bis released
Lab Med traumatic bfell rapidly after brain insults
(2000) brain injury  after its release  and serum levels
following traumatic are positively
brain injury correlated with
the degree of injury
Piazza O
55 Minerva Chir S100B in cardiac  S100b levels Increased levels
(2005) arrest are elevated after  of S100 b12 h
cardiac arrest after a cardiac arrest
might be expression 
of a still amendable 
brain damage
Piazza O
56 Br J Anaesth S100B in severe  Elevated S100 blevels An increase in S100 b











The  study  group  was  composed  of  13
patients  with  atherothrombotic  infarcts  (7
males/6 females, age 73.6±6.75 years, SAPS III
63.9±7.23). Demographic data, mortality and
biochemical  markers  of  study  groups  are
shown in Table 4. 
In  all  the  patients  plasma  levels  of  TAT
increased at all time points, but no significant
differences were observed between day 1 and
day 5. These constantly elevated levels were
associated  with  increased  D-dimer  and  FDP
plasma levels at all time points.
Percent activity of ATIII was not decreased
in ischemic patients on day 1 and 5 after the
ischemic onset. 
No correlation was found between inflam-
matory response (IL-18 and S100B) and proco-
agulant and fibrinolytic markers (ATIII, TAT, D-
dimer and FDP).
IL-18  plasma  levels  were  significantly
(P<0.05) higher at day 1 (309.4±58.4 pg/mL)
and at day 5 (246.7±73.6 pg/mL) compared to
reference value. 
S100B serum levels were significantly high-
er (P=0.004) in stroke patients compared to
normal value.
No  correlation  was  found  between  IL-18
serum  levels  in  focal  ischemic  patients  and
GCS on admission. S100B serum levels were
higher (1.5772 ʼg/mL) in those patients who
had  the  poorer  neurological  examination
(GCS≤8) (P=0.003) (Table 5).
Discussion
In our case series, in contrast to other avail-
able literature data,
49-52 the increase of TAT is
not followed by the reduction of plasma ATIII
activity.  The  elevation  of  D-dimer  and  FDP
without a depletion of ATIII-activity may indi-
cate the presence of active thrombotic lesions
promoting the endogenous fibrinolysis.
Increase in serum IL-18 levels of ischemic
stroke  patients  within  the  first  24-48  hours
after  disease  onset  may  suggest  cytokine
upregulation during acute phase of ischemia.
No  correlation  was  found  between  IL-18
serum  levels  in  focal  ischemic  patients  and
GCS on admission, suggesting that IL-18 could
be considered an early but aspecific marker of
brain injury and its role as a predictive factor
for ischemic outcome should be better investi-
gated.
High S100B serum levels are correlated with
the GCS score.
58 The ischemic-induced cere-
bral S100B release could be the result of a pas-
sive release by damaged cerebral cells and of
an active release by stimulated cerebral cells
initiating  repair  mechanisms,
55-59 but  S100B
serum levels might not reflect the “cerebral”




Thrombin production may be directly related
to thrombus formation or may reflect second-
ary hemostatic activation due to inflammation
and endothelial injury. Antithrombin III is the
most important physiological inhibitor of blood
coagulation as it interferes with the clotting
process at various levels and its deficiency has
been suggested to have an important role in
the pathogenesis and in the evolution of cere-
bral ischemia and might be neuroprotective,
playing an anti inflammatory role.
Activation of coagulation and impairment of
fibrinolysis is mediated by cytokines, with an
enhancement  of  coagulation.  IL-18  is  a  pro-
inflammatory  cytokine  considered  an  impor-
tant marker for monitoring severe inflamma-
tion  conditions  and  it  is  involved  in  early
stroke-induced  inflammation:  increase  in
serum IL-18 levels of ischemic stroke patients
within the first 24-48 hours after disease onset
suggests  cytokine  upregulation  during  acute
phase  of  ischemia.  The  use  of  biochemical
markers of cerebrovascular injury in ischemia,
such as the Calcium-binding protein S100B,
could improve patients care but, unfortunately,
up to now, none of these biochemical markers
can  be  considered  specific  enough  to  guide
clinical decisions. 
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